Clinical trialNCT03776812CompletedPhase 2Interventional

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

SponsorCorcept TherapeuticsEnrollment178Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CancerRecurrent Primary Peritoneal Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sachin Pai, MD
Corcept Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Site Reference Id/investigator #109
Brussels, Belgium
Site Reference Id/investigator #119
Edegem, Belgium
Site Reference Id/investigator #108
Leuven, Belgium

Canada

Site Reference Id/investigator #117
Toronto, Ontario, Canada
Site Reference Id/investigator #096
Montreal, Quebec, Canada

Italy

Site Reference Id/investigator #122
Milan, Italy
Site Reference Id/investigator #112
Naples, Italy
Site Reference Id/investigator #124
Roma, Italy

Spain

Site Reference Id/investigator #115
Barcelona, Spain
Site Reference Id/investigator #114
Madrid, Spain
Site Reference Id/investigator #116
Madrid, Spain
Site Reference Id/investigator #113
Valencia, Spain

United States

Site Reference Id/investigator #004
Birmingham, Alabama, United States
Site Reference Id/investigator #038
Scottsdale, Arizona, United States
Site Reference Id/investigator #032
Denver, Colorado, United States
Site Reference Id/investigator #001
Chicago, Illinois, United States
Site Reference Id/investigator #106
Boston, Massachusetts, United States
Site Reference Id/investigator #128
Boston, Massachusetts, United States
Site Reference Id/investigator #051
New York, New York, United States
Site Reference Id/investigator #169
New York, New York, United States
Site Reference Id/investigator #170
New York, New York, United States
Site Reference Id/investigator #127
Pittsburgh, Pennsylvania, United States
Site Reference Id/investigator #135
Charlottesville, Virginia, United States
Site Reference Id/investigator #121
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Paclitaxel →Relacorilant

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Apr 2019
Primary completion: 16 Mar 2021
Completion: 12 Jul 2023
Last update posted: 7 Oct 2025
Registered enrollment: 178
Registry id: NCT03776812

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.